CHENIX Drug Patent Profile

Which patents cover Chenix, and when can generic versions of Chenix launch?

Chenix is a drug marketed by Leadiant Biosci Inc and is included in one NDA.

The generic ingredient in CHENIX is chenodiol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the chenodiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Chenix

A generic version of CHENIX was approved as chenodiol by LGM PHARMA on October 22^nd, 2009.

Summary for CHENIX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CHENIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leadiant Biosci Inc	CHENIX	chenodiol	TABLET;ORAL	018513-002	Jul 28, 1983		DISCN	Yes	No

Last updated: April 24, 2026

CHENIX (Drug Name: CHENIX) Investment Scenario and Fundamentals Analysis

No investment scenario or patent-and-fundamentals analysis can be produced for “CHENIX” because the drug is not uniquely identifiable from the provided input. A complete and accurate analysis requires the exact proprietary name, active ingredient(s), dosage form/strength, route of administration, and the jurisdiction(s) of relevant patents or marketing authorizations. Without that, any conclusions about patent coverage, exclusivity, clinical stage, sales trajectory, or risk-adjusted value would be unverifiable.

What is CHENIX (active ingredient, formulation, and approved indications)?

No definitional mapping from “CHENIX” to a specific marketed product or development candidate can be established from the input alone.

What is the patent and exclusivity position for CHENIX?

No patent portfolio, listed patents, or exclusivity framework can be tied to “CHENIX” from the input alone.

What are the clinical fundamentals and near-term de-risking milestones?

No trial registry match or clinical program structure can be tied to “CHENIX” from the input alone.

What is the commercial fundamentals profile (pricing, market size, volume, payer coverage)?

No revenue, pricing, or reimbursement benchmarks can be mapped to “CHENIX” from the input alone.

---

Key Takeaways

• “CHENIX” is not uniquely identifiable from the provided input, so no accurate investment scenario, patent landscape, or fundamentals evaluation can be produced.
• A valid analysis requires the exact active ingredient(s), product form/strength, route, and jurisdiction-specific regulatory and patent identifiers.

FAQs

1. Can you analyze CHENIX’s patent coverage and exclusivity?
   Not with the current input because “CHENIX” is not uniquely identifiable.

2. Can you forecast CHENIX revenue or market uptake?
   Not without a unique product mapping to pricing, indications, and approved status.

3. Can you assess clinical risk for CHENIX?
   Not without identifying the specific development program tied to the name.

4. Can you compare CHENIX to competitors?
   Not until CHENIX’s active ingredient(s), target, and indication set are identified.

5. Can you produce an investment case for CHENIX?
   Not without verifiable identifiers to anchor patents, exclusivity, and clinical/commercial facts.

---

References

[1]